Phase II evaluation of bisantrene in metastatic breast cancer.
D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D009362:Neoplasm Metastasis; D010689:Phlebitis / Q000139:chemically induced
D000873:Anthracenes; C031404:bisantrene